Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767550 | 0.82 | TSHR (0.48) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL27594587 | 0.79 | TSHR (0.43) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL1933921 | 0.79 | TSHR (0.43) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL57069 | 0.77 | TSHR (0.52) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL2552585 | 0.77 | TSHR (0.46) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL3333968 | 0.77 | TDP1 (0.42) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL10405739 | 0.76 | TSHR (0.44) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL5065087 | 0.76 | TSHR (0.41) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| Lithium SCHEMBL31366079 | 0.75 | TSHR (0.50) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL8865453 | 0.75 | TSHR (0.50) | TSHRTDP1MAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100430-A1 | Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol | LONZA AG (CH) | 2006-05-11 | — | — | US | claimed |
| EP-1592672-A2 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | Lonza Ltd (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004066905-A3 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | LONZA AG (CH) | 2005-01-20 | — | — | WO | claimed |
| WO-2004066905-A2 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | LONZA LTD (CH) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100430-A1 | Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol | CLCN2, CLIC1, CLIC4 | TSHR 678/4885TDP1 3883/4885MAPT 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.